Vaccine Research & Development

Charles River supports vaccine research and development in both the preclinical and clinical phases of discovery, including in vitro immune profiling, cell biology mechanism of action studies, immunogenicity testing, challenge and protection models, and stability and safety. Our unique combination of expertise in immunology and infection studies makes us an ideal partner to support your vaccine research – from identification of potential targets to analysis of the immune response and assessment in an infectious challenge model.

Examples of how we can help you with your vaccine discovery program include:

  • IN VIVO IMMUNOGENICITY STUDIES

    We can help you take your novel vaccine formulations in vivo – testing their ability to stimulate T- and B-cell responses using different delivery routes. We provide data to help you assess the relative potencies of your different formulations by characterizing and quantifying the antibodies produced and characterizing the magnitude and the nature of the T-cell response.

    data showing the frequency of interferon-gamma producing CD8+ cells in the tissues following vaccination
    Graph showing the frequency of interferon-gamma producing CD8+ cells in the tissues following vaccination

    Figures 1 and 2: Charles River tests the ability of your vaccine to induce specific cytotoxic T-cell responses by determining the frequency of interferon-gamma-producing CD8+ cells in the tissues following vaccination.

  • CHALLENGE & PROTECTION STUDIES

    As the ultimate test of your vaccine, we test efficacy using a wide range of infection models and have the capacity to develop models specific to your needs.

  • IN VITRO IMMUNE PROFILING

    We test the ability of your novel vaccine antigens to invoke an immune response with our human and animal cell cultures. Our dedicated cell biology team use state-of-the-art methods to not only assess cell proliferation and activation, but also to characterize the nature of the immune response to your antigens.

  • TESTING OF NOVEL ADJUVANTS & ANTIGEN DELIVERY VECTORS

    We look at antigen uptake by antigen-presenting cells (APCs) and assess cell activation using a variety of methods, including flow cytometry, cell imaging, and functional assays.

Available assays include:

  • Cell-based assays
  • Immune modulation assays (ELISA, Luminex, and FACS)
  • Cytotoxicity assays